Drug Search Results
More Filters [+]

DS-2248

Alternative Names: ds-2248, ds2248, ds 2248
Latest Update: 2021-10-05
Latest Update Note: Clinical Trial Update

Product Description

a new anticancer drug in subjects with advanced solid tumors. an Orally Bioavailable Heat Shock Protein 90 Inhibitor (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01288430)

Mechanisms of Action: HSP90 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DS-2248

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DS2248-A-U101

P1

Terminated

Non-Small-Cell Lung Cancer

2014-02-13

Recent News Events

Date

Type

Title